Ernexa TherapeuticsERNA -5.30%30 Market Cap is $8.13 Mil as of Jun. 28, 2026. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,429 Biotechnology companies, Ernexa Therapeutics ranks worse than 86.56% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ernexa Therapeutics's share price for the quarter that ended in Mar. 2026 was $4.975. Ernexa Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1.17 Mil. Therefore, Ernexa Therapeutics's market cap for the quarter that ended in Mar. 2026 was $5.80 Mil.
Ernexa Therapeutics's quarterly market cap
increased
from Sep. 2025 ($8.60 Mil) to Dec. 2025 ($9.42 Mil) but then
declined
from Dec. 2025 ($9.42 Mil) to Mar. 2026 ($5.80 Mil).
Ernexa Therapeutics's annual market cap
increased
from Dec. 2023 ($9.42 Mil) to Dec. 2024 ($15.10 Mil) but then
declined
from Dec. 2024 ($15.10 Mil) to Dec. 2025 ($9.42 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ernexa Therapeutics's Enterprise Value for Today is $-0.66 Mil.
Ernexa Therapeutics (NAS:ERNA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ernexa Therapeutics Market Cap Related Terms
Ernexa Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Ernexa Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ernexa Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ernexa Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ernexa Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Ernexa Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ernexa Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ernexa Therapeutics (ERNA) has a Market Cap of $8.13 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ernexa Therapeutics and its competitors. According to the industry distribution chart, Ernexa Therapeutics ranks #1237 out of 1429 companies in the Biotechnology industry, placing it in the top 86.6%.
Is Ernexa Therapeutics' Market Cap too high?
Ernexa Therapeutics' current Market Cap is $8.13 Mil. The Biotechnology industry median Market Cap is 112.70. Ernexa Therapeutics' value of $8.13 Mil is 92.8% below this industry median. Based on the distribution chart, Ernexa Therapeutics ranks #1237 out of 1429 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' Market Cap compare to KPRX and PHGE?
According to the Biotechnology industry distribution chart, Ernexa Therapeutics ranks #1237 out of 1429 companies for Market Cap. This places Ernexa Therapeutics in the lower half of its industry. The industry median Market Cap is 112.70. Ernexa Therapeutics' value of $8.13 Mil is 92.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ernexa Therapeutics's current Market Cap of $8.13 Mil is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ernexa Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ernexa Therapeutics's current Market Cap is $8.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current Market Cap of $8.13 Mil. The current Market Cap is $8.13 Mil and 92.8% below the Biotechnology industry median of 112.70. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current Market Cap is $8.13 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score
Get the complete analysis for ERNA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERNA has been successfully added to your 
